14 February 2016

Seeing in 3D

18/07/11 Ben Jaglom

Eye tracking specialist Seeing Machines (SEE) has won a deal to supply its technology to Toshiba’s new glasses-free laptop.

The AIM-quoted Australian minnow will be supplying its faeAPI technology- which tracks the movement of the eyeball – for Toshiba’s Qosmio F750, which the company enthuses is the world’s first 3D laptop to not require special glasses. The company will receive a royalty for each unit sold by Toshiba. It is built into the laptop’s webcam which then tracks the movement of the eyeball to produce a 3D image.

Seeing's CEO Ken Kroeger declared that it is 'only the beginning of a new era in glasses-free 3D'. He enthused that SuperD (its partner in the technology) chose Seeing as it develops technology that is 'uniquely able to provide face tracking with the required accuracy and reliability' adding that he believes this launch is 'the first of many.'

Prior to the announcement analysts at paid-for research house Edison were forecasting pre-tax profits of AUD $1.3 million (£850,000) on sales of AUD$ 8.7 million for the year to June 2011. In 2012 it is pencilling in profits of AUD $1.9 million on turnover of AUD $10. 8million. EPS of 0.3 cents (0.2p) and 0.4 cents (0.26p) are forecast for 2011 and 2012, respectively.

Recommended by Growth Company Investor last October at 3.5p the shares currently trade at 2.5p. The highly volatile shares have traded between a range of 1p to 4p over the last four years, with the company having done little to generate a significant rerating of its prospects. While the deal should provide some increased momentum we retain our hold rating for now.

Tags: 3D Technology, Australian businesses, Laptops, Technology in Australia

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gresham brings private equity expertise to small listed stocks 11/02/16

There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.

Diurnal to profit from orphan drugs 09/02/16

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling 05/02/16

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair! 04/02/16

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough 01/02/16

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced 29/01/16

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

More News